Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01146834 · ClinicalTrials.gov registry record · Phase 3
Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma
A Phase 3 study, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- Phase 3
- Development phase
- 47
- Enrollment target
NCT01146834 is a Phase 3 study that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 47 participants.
The verdict
NCT01146834, a Phase 3 study, has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 47 participants
- Enrollment target
Study Summary
This phase III randomized trial compares three different peripheral stem cell mobilization regimens for patients with multiple myeloma who have received primary induction therapy or other therapies. Up to 180 patients will be enrolled. Patients eligible for treatment will be randomized to one of the three following mobilization regimens: Arm A = VELCADE, CYCLOPHOSPHAMIDE, \& G-CSF Arm B = VELCADE \& G-CSF Arm C = CYCLOPHOSPHAMIDE \& G-CSF Arm D = PLERIXAFOR \& G-CSF Arm E = PLERIXAFOR, VELCADE, \& G-CSF
Interventions
- DRUG G-CSF
- DRUG Plerixafor
- DRUG cyclophosphamide
- DRUG bortezomib (Velcade)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2011-03 |
| Est. Completion | 2019-02-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01146834
The ClinicalTrials.gov registry entry for NCT01146834 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which G-CSF is the first listed.
NCT01146834 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01146834 about?
NCT01146834 is a clinical study titled "Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma". This phase III randomized trial compares three different peripheral stem cell mobilization regimens for patients with multiple myeloma who have received primary induction therapy or other therapies. Up to 180 patients will be enrolled. Patients eligible for treatment will be randomized to one of the...
What is the current status of trial NCT01146834?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 47 participants. The study started on 2011-03. Estimated completion is 2019-02-04.
What interventions are being tested in trial NCT01146834?
The interventions under investigation include: G-CSF (DRUG), Plerixafor (DRUG), cyclophosphamide (DRUG), bortezomib (Velcade) (DRUG).
Who is sponsoring clinical trial NCT01146834?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.